FourThought Financial Partners LLC Sells 5,661 Shares of Johnson & Johnson (NYSE:JNJ)

FourThought Financial Partners LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,790 shares of the company’s stock after selling 5,661 shares during the period. FourThought Financial Partners LLC’s holdings in Johnson & Johnson were worth $6,478,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. State Street Corp increased its position in Johnson & Johnson by 0.9% during the third quarter. State Street Corp now owns 134,245,811 shares of the company’s stock worth $21,755,874,000 after acquiring an additional 1,154,088 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company’s stock worth $9,064,149,000 after acquiring an additional 1,004,763 shares during the period. FMR LLC increased its stake in Johnson & Johnson by 7.4% in the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after acquiring an additional 1,265,748 shares during the period. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after purchasing an additional 102,502 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after purchasing an additional 1,729,281 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $163.69 on Friday. The firm’s 50 day moving average price is $150.48 and its two-hundred day moving average price is $156.02. The stock has a market cap of $394.11 billion, a PE ratio of 24.62, a PEG ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.03%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on JNJ. Morgan Stanley lowered their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Barclays raised their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.